New publication: Omega-3 Long-Chain Polyunsaturated Fatty Acids in the Elderly: A Review Pietro Gareri. OBM Geriatrics 2022; 6(2), doi:10.21926/obm.geriatr.2202198

Available studies suggest that omega-3 PUFAs exert pleiotropic effects on cognitive decline, mood, the cardiovascular system, bone and muscle health, vascular endothelium, and immune function.

EPA is a more important indicator of omega-3 PUFA intake than DPA or DHA, probably owing to the different ways it is incorporated into membrane phospholipids. The intake of EPA up to 3 g/d is safe and effective.

A recent meta-analysis of 149.051 individuals demonstrated that the cardiovascular risk reduction observed for omega-3 PUFAs is more prominent with EPA in monotherapy (doses ranging from 1.8 to 4.0 g/d) than with EPA + DHA. The meta-analysis confirmed the function of omega3 PUFAs, specifically EPA, in the current treatment for residual cardiovascular risk reduction in patients with atherosclerotic cardiovascular diseases.

You can read the open-access paper here: https://www.lidsen.com/journals/geriatrics/geriatrics-06-02-198